{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:15:07Z","timestamp":1778512507555,"version":"3.51.4"},"reference-count":76,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.ijcard.2009.08.002","type":"journal-article","created":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T08:26:42Z","timestamp":1251793602000},"page":"3-10","source":"Crossref","is-referenced-by-count":40,"title":["Cardiac challenges in patients with Fabry disease"],"prefix":"10.1016","volume":"141","author":[{"given":"F.","family":"Weidemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Linhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Monserrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Strotmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2009.08.002_bib1","series-title":"The metabolic and molecular bases of inherited disease","first-page":"3733","article-title":"a-Galactosidase a deficiency: Fabry disease","author":"Desnick","year":"2001"},{"key":"10.1016\/j.ijcard.2009.08.002_bib2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ijcard.2009.08.002_bib3","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson\u2013Fabry disease: results from the international Fabry Outcome Survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2009.08.002_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2009.08.002_bib5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ijcard.2009.08.002_bib6","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.ijcard.2009.08.002_bib7","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54months of agalsidase \u03b2 therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ijcard.2009.08.002_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijcard.2009.08.002_bib9","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2009.08.002_bib10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijcard.2009.08.002_bib11","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1681\/ASN.2006111263","article-title":"Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing","volume":"18","author":"Schiffmann","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ijcard.2009.08.002_bib12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet Med"},{"key":"10.1016\/j.ijcard.2009.08.002_bib13","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2009.08.002_bib14","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","article-title":"The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease","volume":"26","author":"Weidemann","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2009.08.002_bib15","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00392-005-0284-4","article-title":"Morbus Fabry of the heart. Why should cardiologists care?","volume":"94","author":"Strotmann","year":"2005","journal-title":"Z Kardiol"},{"issue":"Suppl A","key":"10.1016\/j.ijcard.2009.08.002_bib16","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0149-2918(07)80120-2","article-title":"Progression of Fabry cardiomyopathy","volume":"29","author":"Strotmann","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijcard.2009.08.002_bib17","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson\u2013Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"105","author":"Sachdev","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2009.08.002_bib18","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry's disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2009.08.002_bib19","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.CIR.0000139847.74101.03","article-title":"Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy","volume":"110","author":"Chimenti","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2009.08.002_bib20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF01606034","article-title":"Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy","volume":"417","author":"Elleder","year":"1990","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"10.1016\/j.ijcard.2009.08.002_bib21","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/0046-8177(90)90258-7","article-title":"Restricted accumulation of globotriaosylceramide in the hearts of atypical cases of Fabry's disease","volume":"21","author":"Ogawa","year":"1990","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ijcard.2009.08.002_bib22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJM199102073240607","article-title":"An atypical variant of Fabry's disease with manifestations confined to the myocardium","volume":"324","author":"von Scheidt","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2009.08.002_bib23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","article-title":"Onset and progression of the Anderson\u2013Fabry disease related cardiomyopathy","volume":"130","author":"Kampmann","year":"2008","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ijcard.2009.08.002_bib24","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.ATV.0000209649.60409.38","article-title":"Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition","volume":"26","author":"Barbey","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ijcard.2009.08.002_bib25","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ijcard.2009.08.002_bib26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","article-title":"Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells","volume":"95","author":"Shen","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ijcard.2009.08.002_bib27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0168-9525(03)00081-7","article-title":"Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion","volume":"19","author":"Ashrafian","year":"2003","journal-title":"Trends Genet"},{"key":"10.1016\/j.ijcard.2009.08.002_bib28","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1161\/01.CIR.97.25.2536","article-title":"31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy","volume":"97","author":"Jung","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2009.08.002_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymgme.2004.01.011","article-title":"Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts","volume":"82","author":"L\u00fccke","year":"2004","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ijcard.2009.08.002_bib30","unstructured":"Holland WW, Stewart S, Masseria C. Policy brief: screening in Europe. European Observatory on Health Systems and Policies, and World Health Organization, 2006. Available at: http:\/\/www.euro.who.int\/Document\/E88698.pdf (accessed 18 Sept 2008)."},{"key":"10.1016\/j.ijcard.2009.08.002_bib31","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry","volume":"30","author":"Eng","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.ijcard.2009.08.002_bib32","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ijcard.2009.08.002_bib33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1651-2227.2002.tb03105.x","article-title":"Electrocardiographic signs of hypertrophy in Fabry disease-associated hypertrophic cardiomyopathy","volume":"91","author":"Kampmann","year":"2002","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.ijcard.2009.08.002_bib34","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2007.06.062","article-title":"Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy","volume":"50","author":"Monserrat","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2009.08.002_bib35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ndt\/gfl528","article-title":"A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population","volume":"22","author":"Merta","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijcard.2009.08.002_bib36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10897-007-9128-x","article-title":"Diagnosis of Fabry disease via analysis of family history","volume":"17","author":"Laney","year":"2008","journal-title":"J Genet Couns"},{"issue":"Suppl 2","key":"10.1016\/j.ijcard.2009.08.002_bib37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1023\/A:1012428009627","article-title":"Cardiac manifestations in Fabry disease","volume":"24","author":"Linhart","year":"2001","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.ijcard.2009.08.002_bib38","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/ncpcardio1110","article-title":"Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression","volume":"5","author":"Keren","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.ijcard.2009.08.002_bib39","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa033349","article-title":"Glycogen storage diseases presenting as hypertrophic cardiomyopathy","volume":"352","author":"Arad","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2009.08.002_bib40","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/heart.89.8.929","article-title":"Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy?","volume":"89","author":"Ommen","year":"2003","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2009.08.002_bib41","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF00208693","article-title":"Cornea verticillata","volume":"27","author":"Fran\u00e7ois","year":"1969","journal-title":"Doc Ophthalmol"},{"key":"10.1016\/j.ijcard.2009.08.002_bib42","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1399-0004.1991.tb03018.x","article-title":"Hypertrophic cardiomyopathy in late-onset variant of Fabry disease with high residual activity of alpha-galactosidase A","volume":"39","author":"Nagao","year":"1991","journal-title":"Clin Genet"},{"key":"10.1016\/j.ijcard.2009.08.002_bib43","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2215\/CJN.02490607","article-title":"Screening for Fabry disease in patients with chronic kidney disease: limitations of plasma alpha-galactosidase assay as a screening test","volume":"3","author":"Andrade","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ijcard.2009.08.002_bib44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cccn.2004.10.019","article-title":"Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers","volume":"353","author":"Linthorst","year":"2005","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.ijcard.2009.08.002_bib45","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/humu.20144","article-title":"Detection of alpha-galactosidase A mutations causing Fabry disease by denaturing high performance liquid chromatography","volume":"25","author":"Shabbeer","year":"2005","journal-title":"Hum Mutat"},{"key":"10.1016\/j.ijcard.2009.08.002_bib46","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ndtplus\/sfn009","article-title":"Implementation of high-throughput screening for Fabry disease in Toronto dialysis patients","volume":"1","author":"Rasaiah","year":"2008","journal-title":"NDT Plus"},{"key":"10.1016\/j.ijcard.2009.08.002_bib47","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1096-7192(03)00136-7","article-title":"Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma","volume":"80","author":"Froissart","year":"2003","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ijcard.2009.08.002_bib48","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10545-005-0039-4","article-title":"The ratio of alpha-galactosidase to beta-glucuronidase activities in dried blood for the identification of female Fabry disease patients","volume":"28","author":"Lukacs","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.ijcard.2009.08.002_bib49","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s10545-007-0679-7","article-title":"Direct comparison of enzyme measurements from dried blood and leukocytes from male and female Fabry disease patients","volume":"30","author":"Lukacs","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.ijcard.2009.08.002_bib50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0009-8981(01)00478-8","article-title":"Fabry disease: enzymatic diagnosis in dried blood spots on filter paper","volume":"308","author":"Chamoles","year":"2001","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.ijcard.2009.08.002_bib51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/08035320510028111","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"Young","year":"2005","journal-title":"Acta Paediatr Suppl"},{"issue":"4","key":"10.1016\/j.ijcard.2009.08.002_bib52","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10545-007-0607-x","article-title":"Quebec neonatal mass urinary screening programme: from micromolecules to macromolecules","volume":"30","author":"Auray-Blais","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.ijcard.2009.08.002_bib53","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1399-0004.2006.00594.x","article-title":"A successful approach for the detection of Fabry patients in Argentina","volume":"69","author":"Rozenfeld","year":"2006","journal-title":"Clin Genet"},{"key":"10.1016\/j.ijcard.2009.08.002_bib54","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1399-0004.2004.00284.x","article-title":"Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease","volume":"66","author":"Spinelli","year":"2004","journal-title":"Clin Genet"},{"key":"10.1016\/j.ijcard.2009.08.002_bib55","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2009.08.002_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/hrt.2008.162800","article-title":"Effects of enzyme replacement therapy in patients with Anderson\u2013Fabry disease: a prospective long term cardiac magnetic resonance imaging study","author":"Imbriaco","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2009.08.002_bib57","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson\u2013Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase-alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2009.08.002_bib58","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s10545-006-0361-5","article-title":"Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease","volume":"29","author":"Bierer","year":"2006","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.ijcard.2009.08.002_bib59","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.ajkd.2005.03.016","article-title":"Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement","volume":"46","author":"Pisani","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ijcard.2009.08.002_bib60","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","article-title":"Clinical benefit of enzyme replacement therapy in Fabry disease","volume":"69","author":"Breunig","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.ijcard.2009.08.002_bib61","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10545-006-0221-3","article-title":"The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease","volume":"29","author":"Kalliokoski","year":"2006","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.ijcard.2009.08.002_bib62","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/hrt.2004.054015","article-title":"Coronary microvascular dysfunction in male patients with Anderson\u2013Fabry disease and the effect of treatment with alpha galactosidase A","volume":"92","author":"Elliott","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2009.08.002_bib63","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","article-title":"Fabry disease: overall effects of agalsidase alfa treatment","volume":"34","author":"Beck","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ijcard.2009.08.002_bib64","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","article-title":"Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2mg\/kg","volume":"2","author":"Vedder","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijcard.2009.08.002_bib65","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3","volume":"94","author":"Vedder","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ijcard.2009.08.002_bib66","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ymgme.2008.03.008","article-title":"Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease","volume":"94","author":"Ohashi","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ijcard.2009.08.002_bib67","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.ehj.2003.09.017","article-title":"Gadolinium enhanced cardiovascular magnetic resonance in Anderson\u2013Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium","volume":"24","author":"Moon","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2009.08.002_bib68","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1161\/CIRCULATIONAHA.105.584292","article-title":"Images in cardiovascular medicine. Transition from left ventricular hypertrophy to massive fibrosis in the cardiac variant of Fabry disease","volume":"113","author":"Hasegawa","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2009.08.002_bib69","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s10545-006-0360-6","article-title":"Extracellular matrix turnover and disease severity in Anderson\u2013Fabry disease","volume":"30","author":"Shah","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.ijcard.2009.08.002_bib70","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jjcc.2007.12.001","article-title":"Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study","volume":"51","author":"Takenaka","year":"2008","journal-title":"J Cardiol"},{"key":"10.1016\/j.ijcard.2009.08.002_bib71","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/ejechocard\/jen129","article-title":"Anderson\u2013Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy","volume":"9","author":"Kovacevic-Preradovic","year":"2008","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.ijcard.2009.08.002_bib72","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.amjcard.2005.11.087","article-title":"Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy","volume":"97","author":"Beer","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2009.08.002_bib73","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1161\/01.CIR.0000061952.27445.A0","article-title":"Early detection of Fabry cardiomyopathy by tissue Doppler imaging","volume":"107","author":"Pieroni","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2009.08.002_bib74","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijcard.2008.04.075","article-title":"Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy","volume":"132","author":"Toro","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ijcard.2009.08.002_bib75","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1093\/eurheartj\/ehm454","article-title":"A new echocardiographic approach for the detection of non-ischaemic fibrosis in hypertrophic myocardium","volume":"28","author":"Weidemann","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2009.08.002_bib76","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijcard.2008.11.048","article-title":"Ethical authorship and publishing","volume":"131","author":"Coats","year":"2009","journal-title":"Int J Cardiol"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527309008535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527309008535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T12:27:00Z","timestamp":1545049620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527309008535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S0167527309008535"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2009.08.002","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}